NovaBay Pharmaceuticals, Inc.

DB:B9P0 Stock Report

Market Cap: €2.3m

NovaBay Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

NovaBay Pharmaceuticals's earnings have been declining at an average annual rate of -15.8%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 13.5% per year.

Key information

-15.8%

Earnings growth rate

30.8%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate13.5%
Return on equityn/a
Net Margin-120.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How NovaBay Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:B9P0 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2414-17130
31 Mar 2415-19130
31 Dec 2315-17130
30 Sep 2313-15130
30 Jun 2313-19130
31 Mar 2313-17140
31 Dec 2214-16150
30 Sep 2214-9160
30 Jun 2213-5170
31 Mar 2212-5170
31 Dec 2110-7150
30 Sep 219-7130
30 Jun 218-8130
31 Mar 2110-11120
31 Dec 2010-11120
30 Sep 2010-13130
30 Jun 209-10120
31 Mar 207-8120
31 Dec 197-10140
30 Sep 198-8150
30 Jun 1910-10170
31 Mar 1911-9190
31 Dec 1813-7190
30 Sep 1815-4190
30 Jun 1816-5200
31 Mar 1817-6210
31 Dec 1718-7220
30 Sep 1716-10230
30 Jun 1715-11220
31 Mar 1714-12211
31 Dec 1612-13191
30 Sep 169-16202
30 Jun 167-17204
31 Mar 166-19205
31 Dec 154-19196
30 Sep 153-19157
30 Jun 152-18128
31 Mar 151-161011
31 Dec 141-1589
30 Sep 141-15720
30 Jun 142-14617
31 Mar 143-16612
31 Dec 133-16612
30 Sep 134-1470

Quality Earnings: B9P0 is currently unprofitable.

Growing Profit Margin: B9P0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: B9P0 is unprofitable, and losses have increased over the past 5 years at a rate of 15.8% per year.

Accelerating Growth: Unable to compare B9P0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: B9P0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).


Return on Equity

High ROE: B9P0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies